These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
1560 related articles for article (PubMed ID: 12189441)
1. Defective amplification of the late phase insulin response to glucose by GIP in obese Type II diabetic patients. Vilsbøll T; Krarup T; Madsbad S; Holst JJ Diabetologia; 2002 Aug; 45(8):1111-9. PubMed ID: 12189441 [TBL] [Abstract][Full Text] [Related]
2. The pathophysiology of diabetes involves a defective amplification of the late-phase insulin response to glucose by glucose-dependent insulinotropic polypeptide-regardless of etiology and phenotype. Vilsbøll T; Knop FK; Krarup T; Johansen A; Madsbad S; Larsen S; Hansen T; Pedersen O; Holst JJ J Clin Endocrinol Metab; 2003 Oct; 88(10):4897-903. PubMed ID: 14557471 [TBL] [Abstract][Full Text] [Related]
3. Secretion of incretin hormones (GIP and GLP-1) and incretin effect after oral glucose in first-degree relatives of patients with type 2 diabetes. Nauck MA; El-Ouaghlidi A; Gabrys B; Hücking K; Holst JJ; Deacon CF; Gallwitz B; Schmidt WE; Meier JJ Regul Pept; 2004 Nov; 122(3):209-17. PubMed ID: 15491793 [TBL] [Abstract][Full Text] [Related]
4. The insulinotropic effect of GIP is impaired in patients with chronic pancreatitis and secondary diabetes mellitus as compared to patients with chronic pancreatitis and normal glucose tolerance. Knop FK; Vilsbøll T; Højberg PV; Larsen S; Madsbad S; Holst JJ; Krarup T Regul Pept; 2007 Dec; 144(1-3):123-30. PubMed ID: 17692937 [TBL] [Abstract][Full Text] [Related]
5. alpha-Glucosidase inhibition (acarbose) fails to enhance secretion of glucagon-like peptide 1 (7-36 amide) and to delay gastric emptying in Type 2 diabetic patients. Hücking K; Kostic Z; Pox C; Ritzel R; Holst JJ; Schmiegel W; Nauck MA Diabet Med; 2005 Apr; 22(4):470-6. PubMed ID: 15787675 [TBL] [Abstract][Full Text] [Related]
6. Blood glucose control in healthy subject and patients receiving intravenous glucose infusion or total parenteral nutrition using glucagon-like peptide 1. Nauck MA; Walberg J; Vethacke A; El-Ouaghlidi A; Senkal M; Holst JJ; Gallwitz B; Schmidt WE; Schmiegel W Regul Pept; 2004 Apr; 118(1-2):89-97. PubMed ID: 14759561 [TBL] [Abstract][Full Text] [Related]
7. Subcutaneous glucagon-like peptide-1 improves postprandial glycaemic control over a 3-week period in patients with early type 2 diabetes. Todd JF; Edwards CM; Ghatei MA; Mather HM; Bloom SR Clin Sci (Lond); 1998 Sep; 95(3):325-9. PubMed ID: 9730852 [TBL] [Abstract][Full Text] [Related]
8. Dissociated effects of glucose-dependent insulinotropic polypeptide vs glucagon-like peptide-1 on beta-cell secretion and insulin clearance in mice. Pacini G; Thomaseth K; Ahrén B Metabolism; 2010 Jul; 59(7):988-92. PubMed ID: 20153002 [TBL] [Abstract][Full Text] [Related]
9. Prolonged and enhanced secretion of glucagon-like peptide 1 (7-36 amide) after oral sucrose due to alpha-glucosidase inhibition (acarbose) in Type 2 diabetic patients. Seifarth C; Bergmann J; Holst JJ; Ritzel R; Schmiegel W; Nauck MA Diabet Med; 1998 Jun; 15(6):485-91. PubMed ID: 9632123 [TBL] [Abstract][Full Text] [Related]
10. Initially more rapid small intestinal glucose delivery increases plasma insulin, GIP, and GLP-1 but does not improve overall glycemia in healthy subjects. Chaikomin R; Doran S; Jones KL; Feinle-Bisset C; O'Donovan D; Rayner CK; Horowitz M Am J Physiol Endocrinol Metab; 2005 Sep; 289(3):E504-7. PubMed ID: 15886226 [TBL] [Abstract][Full Text] [Related]
11. Lack of effect of exendin-4 and glucagon-like peptide-1-(7,36)-amide on insulin action in non-diabetic humans. Vella A; Shah P; Reed AS; Adkins AS; Basu R; Rizza RA Diabetologia; 2002 Oct; 45(10):1410-5. PubMed ID: 12378382 [TBL] [Abstract][Full Text] [Related]
12. Incretin hormone secretion in women with polycystic ovary syndrome: roles of obesity, insulin sensitivity, and treatment with metformin. Svendsen PF; Nilas L; Madsbad S; Holst JJ Metabolism; 2009 May; 58(5):586-93. PubMed ID: 19375579 [TBL] [Abstract][Full Text] [Related]
13. Near-normalisation of diurnal glucose concentrations by continuous administration of glucagon-like peptide-1 (GLP-1) in subjects with NIDDM. Rachman J; Barrow BA; Levy JC; Turner RC Diabetologia; 1997 Feb; 40(2):205-11. PubMed ID: 9049482 [TBL] [Abstract][Full Text] [Related]
14. Addition of metformin to exogenous glucagon-like peptide-1 results in increased serum glucagon-like peptide-1 concentrations and greater glucose lowering in type 2 diabetes mellitus. Cuthbertson J; Patterson S; O'Harte FP; Bell PM Metabolism; 2011 Jan; 60(1):52-6. PubMed ID: 20152998 [TBL] [Abstract][Full Text] [Related]
15. Predictors of incretin concentrations in subjects with normal, impaired, and diabetic glucose tolerance. Vollmer K; Holst JJ; Baller B; Ellrichmann M; Nauck MA; Schmidt WE; Meier JJ Diabetes; 2008 Mar; 57(3):678-87. PubMed ID: 18057091 [TBL] [Abstract][Full Text] [Related]
17. Exaggerated secretion of glucagon-like peptide-1 (GLP-1) could cause reactive hypoglycaemia. Toft-Nielsen M; Madsbad S; Holst JJ Diabetologia; 1998 Oct; 41(10):1180-6. PubMed ID: 9794105 [TBL] [Abstract][Full Text] [Related]
18. No effect of beta-adrenergic blockade on hypoglycaemic effect of glucagon-like peptide-1 (GLP-1) in normal subjects. Toft-Nielsen M; Hvidberg A; Hilsted J; Dige-Petersen H; Holst JJ Diabet Med; 1996 Jun; 13(6):544-8. PubMed ID: 8799658 [TBL] [Abstract][Full Text] [Related]
19. Incretin secretion in relation to meal size and body weight in healthy subjects and people with type 1 and type 2 diabetes mellitus. Vilsbøll T; Krarup T; Sonne J; Madsbad S; Vølund A; Juul AG; Holst JJ J Clin Endocrinol Metab; 2003 Jun; 88(6):2706-13. PubMed ID: 12788877 [TBL] [Abstract][Full Text] [Related]
20. Similar elimination rates of glucagon-like peptide-1 in obese type 2 diabetic patients and healthy subjects. Vilsbøll T; Agersø H; Krarup T; Holst JJ J Clin Endocrinol Metab; 2003 Jan; 88(1):220-4. PubMed ID: 12519856 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]